Chymase inhibition and cardiovascular protection

Cardiovascular Drugs and Therapy

Volumn 27, Issue 2, 2013, Pages 139-143

  Tojo, Hideaki ^a   Urata, Hidenori ^a  

^a Fukuoka University Chikushi Hospital   (Japan)

Author keywords

Angiotensin II; Local reninangiotensin system; Serine proteinase

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CHYMASE; CHYMASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL; SERINE PROTEINASE; TEMOCAPRIL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; HEART FAILURE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY INJURY; MICROALBUMINURIA; MOLECULAR PATHOLOGY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

ANGIOTENSIN II; ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CHYMASES; HUMANS; SERINE PROTEASES;

EID: 84878301906     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-013-6450-4     Document Type: Review

References (25)

1. Dzau VJ. Molecular and physiological aspects of tissue reninangiotensin system: emphasis on cardiovascular control. J Hypertens. 1988;6(supplement):S7- 12.
2. Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation. 1988;77:I4-13.
3. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid angiotensin i and angiotensin ii concentrations during local angiotensinconverting enzyme inhibition. J Am Soc Nephrol. 2002;13:2207- 12.
4. Urata H, Nishimura H, Ganten D. Chymase-dependent angiotensin ii forming systems in humans. Am J Hypertens. 1996;9:277-84.
5. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, et al. Cellular localization and regional distribution of an angiotensin ii-forming chymase in the heart. J Clin Invest. 1993;91:1269-81.
6. Li M, Liu K, Michalicek J, Angus JA, Hunt JE, Dell'Italia LJ, et al. Involvement of chymase-mediated angiotensin ii generation in blood pressure regulation. J Clin Invest. 2004;114:112-20.
7. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.
8. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan in Acute Myocardial Infarction Trial I. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906.
9. Adachi Y, Saito Y, Kishimoto I, Harada M, Kuwahara K, Takahashi N, et al. Angiotensin ii type 2 receptor deficiency exacerbates heart failure and reduces survival after acute myocardial infarction in mice. Circulation. 2003;107:2406-8.
10. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9.
11. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60.
12. Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, et al. Possible inhibition of focal cerebral ischemia by angiotensin ii type 2 receptor stimulation. Circulation. 2004;110:843-8.
13. Ihara M, Urata H, Kinoshita A, Suzumiya J, Sasaguri M, Kikuchi M, et al. Increased chymase-dependent angiotensin ii formation in human atherosclerotic aorta. Hypertension. 1999;33:1399-405.
14. Ihara M, Urata H, Shirai K, Ideishi M, Hoshino F, Suzumiya J, et al. High cardiac angiotensin-ii-forming activity in infarcted and non-infarcted human myocardium. Cardiology. 2000;94:247-53.
15. Uehara Y, Urata H, Sasaguri M, Ideishi M, Sakata N, Tashiro T, et al. Increased chymase activity in internal thoracic artery of patients with hypercholesterolemia. Hypertension. 2000;35:55-60.
16. Murakami K, Uehara Y, Abe S, Inoue Y, Ideishi M, Saku K, et al. Positive correlation between chymase-like angiotensin ii-forming activity in mononuclear cells and serum cholesterol level. J Cardiol. 2007;50:291-8.
17. Okamura K, Inoue Y, Uehara Y, Maruyama S, Sumi S, Furuyama S, et al. Chymase dependent angiotensin ii-forming activity in the circulating mononuclear leukocyte increases post acute myocardial infarction the 73rd annual scientific meeting of the japanese circulation society. Circ J. 2009;73:490.
18. Hoshino F, Urata H, Inoue Y, Saito Y, Yahiro E, Ideishi M, et al. Chymase inhibitor improves survival in hamsters with myocardial infarction. J Cardiovasc Pharmacol. 2003;41 Suppl 1:S11-8.
19. Wei CC, Hase N, Inoue Y, Bradley EW, Yahiro E, Li M, et al. Mast cell chymase limits the cardiac efficacy of ang i-converting enzyme inhibitor therapy in rodents. J Clin Invest. 2011;120:1229-39.
20. Shiota N, Jin D, Takai S, Kawamura T, Koyama M, Nakamura N, et al. Chymase is activated in the hamster heart following ventricular fibrosis during the chronic stage of hypertension. FEBS Lett. 1997;406:301-4.
21. Uehara Y, Urata H, Ideishi M, Arakawa K, Saku K. Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta. Cardiovasc Res. 2002;55:870- 6.
22. Maeda Y, Inoguchi T, Takei R, Sawada F, Sasaki S, Fujii M, et al. Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters. Am J Physiol. 2010;299: F1328-38.
23. Chandrasekharan UM, Sanker S, Glynias MJ, Karnik SS, Husain A. Angiotensin ii-forming activity in a reconstructed ancestral chymase. Science. 1996;271:502-5.
24. Akasu M, Urata H, Kinoshita A, Sasaguri M, Ideishi M, Arakawa K. Differences in tissue angiotensin ii-forming pathways by species and organs in vitro. Hypertension. 1998;32:514-20.
25. Wei CC, Hase N, Inoue Y, Bradley EW, Yahiro E, Li M, et al. Mast cell chymase limits the cardiac efficacy of ang i-converting enzyme inhibitor therapy in rodents. J Clin Invest. 2010;120:1229-39.